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Eosinophilic esophagitis is a chronic immune/antigen mediated inflammatory disease of
the esophagus. It comprises a separate entity of increasing incidence and prevalence in chil-
dren and adults.The disease is characterized by histological evidence of dense esophageal
tissue eosinophilia in the presence of a variety of upper GI symptoms including vomiting,
dysphagia, food impaction, and odynophagia. Cornerstone of treatment is dietary interven-
tion and/or the off-label use of swallowed topical corticosteroids. New drug therapies are
under investigation. In this review, we focus on the diagnostic approach and the currently
available treatment strategies.
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INTRODUCTION
Eosinophilic esophagitis (EoE) is a chronic immune/antigen medi-
ated esophageal inflammatory disease associated with esophageal
dysfunction, resulting from severe eosinophil-predominant
inflammation (1). The prevalence of the disease varies from
0.89/10,000 in Western Australia (2) to 4/10,000 children in Ohio
(3) while, in Europe, the incidence of the disease was reported to be
0.16/10,000 in Southern Denmark (4). A recent paper reveals that
incidence and prevalence has increased considerably throughout
the world (5). Exact epidemiologic figures depend on availability
of endoscopy services, medical awareness, and diagnostic protocol.
Eosinophilic esophagitis is a disease with several pheno-
types [e.g., structuring/gastro esophageal reflux disease (GERD)-
like/dysmotility], which need to be better defined in order to clarify
long-term complications such as the development of fibrosis. The
disease is more common in males and in patients with atopic
diseases (6). Studies conducted in children suggest that in many
patients, symptoms of EoE are triggered by food allergens (1).
Experimental models suggest that other sources of antigen expo-
sure beyond food may also cause EoE (7) and a recent report
describes three adults developing EoE after clearly identified expo-
sure to aeroallergens (8). Whether this occurs also in pediatric
patients remains to be demonstrated, although seasonal exacerba-
tion of the disease has been reported in children with EoE (9). The
elimination of specific foods from the patient’s diet is associated
with disease remission while, their reintroduction induces relapse.
However, the methodology for identification of potentially signif-
icant food- or aero-antigens requires further development as the
currently available allergy tests often give false positive or false
negative results leading to the incomplete elimination of causative
food allergens from the patient’s diet and to inability to resolve
symptoms and histological abnormalities. The first consensus rec-
ommendations for diagnosis and treatment of EoE were published
in 2007 by a group of experts who updated them in 2011 (1) while,
more recent guidelines were published by American College of
Gastroenterology (10), and the ESPGHAN (11). The latter, pro-
vided practical management guidelines of childhood EoE based on
evidence where available and on expert opinion where evidence
was lacking, and also, practical diagnostic and management algo-
rithms to guide pediatric gastroenterologists in clinical practice.
In the present review, we discuss diagnosis and treatment options
of childhood EoE.
CLINICAL MANIFESTATIONS OF EoE AND DIAGNOSTIC
APPROACH
The clinical manifestations of EoE are variable depending on
age and the disease phenotypes. Feeding difficulties are the most
common symptoms in infants and toddlers, vomiting and pain
in children, and dysphagia and food impaction in adolescents.
Patients with EoE may or may not be atopic. Total IgE and specific
IgE to food antigens (RAST tests) are not reliable for the identifica-
tion of causative foods of EoE. Skin prick tests (SPT) and allergen
patch tests (APT) can be used but the latter need validation and
are not available everywhere. The foods that are considered for
testing with skin SPT and APT tests include milk protein, egg,
peanuts, soy, a variety of grains (wheat, rice, corn, rye, oats, and
barley), meats (beef, pork, chicken, and turkey), fish, and shellfish.
The positive predictive values of SPTs in children with EoE were
reported to range between 26 and 86% (highest for milk) while
the negative predictive values ranged between 29 and 99% (highest
for peanut) (6). The sensitivity and specificity of the tests varied
between 18–88 and 82–97%, respectively (6). Therefore, isolated
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SPTs may have a better value to exclude rather to confirm relation
to specific foods. The combination of SPTs and APT tests increased
the negative predictive value to an average of 92% with the excep-
tion of milk (at 44%), while the positive predictive value remained
low (at 44%) (6). As the most common food triggers of EoE the
following have been recognized: milk (55%), wheat (33%), nuts
(33%), and seafood (11%) in adults (12) with EoE while, in chil-
dren (6), milk was the most common food identified, followed by
wheat, soy, and eggs (6). The use of allergy tests is limited by com-
mon false positive and false negative results. The identification of
food allergens in patients with EoE may mean concomitant food
allergy without those foods being the precipitating cause of the
disease. On the other hand, elimination diets may still contain the
offending product in occult form leading to refractoriness to the
elimination diet.
Unfortunately, there are no available specific biomarkers for
the diagnosis of the disease, the monitoring of the response to
treatment, and the disease prognosis. Therefore, the disease diag-
nosis relies currently only on endoscopy and histology (3). The
endoscopic features of the disease vary from normal esophagus
to the presence of esophageal rings, furrows, and/or white exu-
dates (Figures 1A–C) indicative of eosinophilic microabscesses
and less often narrowing of the caliber of esophagus (13). The
presence of mucosal breaks (erosions or ulceration) are not indica-
tive of EoE but of GERD, Crohn’s disease, or other diagnoses.
The main histologic feature of EoE is striking eosinophilia of
esophageal mucosa, usually along with microabscesses, superfi-
cial layering, or extracellular eosinophil granules (Figure 2). The
presence of at least 15 eosinophils per high-power field found in
at least 1 esophageal mucosal biopsy (peak value) is required for
the histological definition of the disease. At least three esophageal
biopsies are needed from different parts of esophagus to achieve
a diagnosis of EoE in 97% of patients (14) and five, to achieve
a diagnosis of EoE in 100% (15). The need for multiple biop-
sies derives from the fact that eosinophils are recruited from
the deeper layers of the esophageal wall and areas with lower
eosinophil density may exist in endoscopic superficial mucosal
biopsies (16). If we rely, therefore, on a limited number of super-
ficial mucosal biopsies, the diagnosis of EoE may be missed.
Furthermore, it should be noted that esophageal eosinophilia is
not an exclusive feature of EoE. Other diseases that are associated
with esophageal eosinophilia are GERD, Crohn’s disease, connec-
tive tissue disease, infectious esophagitis (herpes, Candida), celiac
disease, achalasia, graft-versus-host disease, drug hypersensitiv-
ity, eosinophilic gastroenteritis, and hyper eosinophilic syndrome
(1, 17). Gastric and duodenal biopsies should also be taken on
first diagnostic endoscopy to identify or exclude other conditions
like eosinophilic gastroenteropathy. The discussion of this poorly
characterized disease is beyond the scope of this paper. GERD is
the main differential diagnosis from EoE. GERD can present with
similar symptoms as EoE or even co-exist with EoE. There are
studies proposing scoring systems to differentiate between GERD
and EoE, based on clinical and endoscopic features: male gender,
dysphagia, history of food impaction, absence of pain/heartburn,
linear furrowing, and white papules (18). Such systems may be use-
ful in older children and in adolescents (18). The identification of
mucosal inflammatory mediators related to eosinophil activation
FIGURE 1 | Endoscopic appearance of EoE showing (A) friability of the
mucosa and easy bleeding; (B) trachealisation of esophagus with
remains of recent food impaction; and (C) edema with furrows and
white spots of eosinophil granulomas.
has also been tested and may give new diagnostic options and
accuracy (19). Until more data become available, however, there
is a wide consensus that patients need endoscopic and histologic
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FIGURE 2 | Histology of EoE with marked infiltration of eosinophils in
the mucosa.
assessment after a course of 2 months trial with antisecretory drugs
(proton-pump inhibitors, PPIs). Those patients with esophageal
eosinophilia who improve both clinically and histologically after
the treatment with PPIs are currently classified as having either
GERD or PPI-responsive esophageal eosinophilia (PPI-REE). Fur-
ther studies are required to show whether PPI-REE is a separate
entity or it comprises a subtype of EoE or GERD. The ability of
PPIs to achieve resolution of esophageal eosinophilia is attrib-
uted to acid-suppression but also to possible inhibition of various
other inflammatory mechanisms (1, 20, 21). The lack of response
to high-dose proton-pump inhibitors is necessary to fulfill the cur-
rent definition criteria for the disease (1, 11). The recommended
dose of PPIs is 1 mg/kg per dose, twice daily with maximum
dose reaching adult dose 20–40 mg once or twice daily depend-
ing on patient and PPI. After the confirmation of the diagnosis
of EoE, PPIs are usually stopped unless there is evidence of coex-
isting GERD. In that case, PPIs may be continued as adjunctive
therapy to other specific for EoE interventions (1). A practical algo-
rithm on the diagnostic approach of children and adolescents with
symptoms suggesting EoE is given in the position paper recently
published by ESPGHAN (11).
MANAGEMENT OF EoE
The goals of treatment of EoE are to achieve and maintain clinical
and histological remission of the disease and to prevent iatrogenic
damage such as nutritional compromise due to long-term elim-
ination diet. Until minimal invasive tests measuring biochemical
products of eosinophil activation are available to facilitate ade-
quate monitoring of the inflammatory process, the confirmation
of histological remission of the disease with repeat endoscopy and
biopsies before food reintroduction or drug titration, is necessary.
Dietary elimination and/or the off-label use of topical corti-
costeroids is usually associated with reversal of symptoms and
histological abnormalities of the esophagus. A practical algorithm
to treatment approach is given in the position paper recently pub-
lished by ESPGHAN (11). It should be noted, however, that the
optimal intervention needs to be individualized as atopic patients
most likely benefit from the elimination diet and the non-atopic
from steroids. Unfortunately, it is not always easy to identify the
causative foods while, not all of the atopic patients are sensitized
to the same foods and others are sensitized to aero allergens.
DIETARY TREATMENT
Three elimination diets have been developed for patients with EoE:
(1) amino acid-based formula (AAF); (2) targeted elimination diet
(TED); and (3) empiric elimination diet (EED).
Case series suggest all of the above diets are effective in inducing
clinical and histological remission in patients with EoE (6, 22–28)
with AAF being the most successful (Table 1), It should be noted,
however, that, to date, there are no randomized controlled trials
investigating the efficacy of any of these diets. There also has not
been any head-to-head comparison of these different modes of
treatment and different centers have developed varying levels of
expertise in administration of them, which is likely to influence
management preference.
The AAF consists of complete removal of food allergens from
the diet substituted by a hypoallergenic formula based on amino
acids (23). Several studies reported efficacy of AAF in achiev-
ing clinical and histological remission of EoE in both children
(22, 24) and in adults (28). Resolution of clinical symptoms such
as vomiting, abdominal pain, or dysphagia in children (22, 24) and
dysphagia, chest pain, food impaction, or heartburn in adults (28),
was reported as early as at 8 days (22) or at 2 weeks (24, 28) of intro-
duction while, histological resolution was reported at 4 weeks (22,
24, 28). Despite these encouraging reports of remission induc-
tion, long-term use of the AAF is severely curtailed by its many
disadvantages including the high cost of AAF and the frequent
need for nasogastric tube placement or even gastrostomy due to
poor long-term palatability. Currently, AAF is reserved for young
infants with multiple food allergies as well as for patients who do
not respond or do not wish to follow strict diet with multiple food
elimination.
Owing to the poor long-term acceptability of AAF, the TED,
which removes foods based on a combination of suggestive his-
tory of food triggers and results of SPTs and (in some centers) APT
was evaluated. The benefit of TED to induce remission in children
has been variable from non- to moderate (29) or high (6) among
those with positive SPTs and/or APT. It should be noted, however,
that some patients with EoE have intolerance to multiple food
antigens some of which may have not been identified by skin tests.
Furthermore, the identified food antigens with SPTs and/or APT
may not necessarily be the causative foods of the disease. There-
fore, relying only on tests, which have often false positive or false
negative results may lead to elimination from the diet of only part
of the offending food antigens, and failure to induce remission.
Another dietary strategy for treating EoE is with the use of
EED, which removes from the diet independently of sensitization,
the known allergens that strongly correlate with EoE, which are
often the dairy products, soy, eggs, wheat, peanuts, fish, and shell-
fish (27). This diet strategy has been used in treating children
with EoE achieving clinical and histological improvement in 74%
of patients (27), although a more recent study reported a lower
percentage of the patients showing histological remission (53% of
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Table 1 | Outcomes of studies on dietary treatment of eosinophilic esophagitis.
Reference No of patients Diet Duration Outcome
Kelly et al. (23) 10 Children AAF Min. 6 weeks Significant clinical and histology improvement in all
Markowitz et al. (22) 51 Children AAF 4 weeks Significant improvement in all
Henderson et al (24) 90 Children AAF 49 Aver. 18 weeks Histologic remission in 96%
SFED 26 Aver. 18 weeks Histologic remission in 81%
TED 15 Aver. 16 weeks Histologic remission in 63%
Kagalwalla et al. (27) 60 Children AAF 25 Min. 6 weeks Significant improvement AAF 88%
SFED 35 Significant improvement SFED 74%
Gonsalves et al. (25) 50 Adults SFED 6 weeks Significant clinical improvement in 94%
Histological improvement in 70%
Spergel et al. (30) 146 Children TED 4–8 weeks Significant improvement 77%
Partial improvement 13%
Treatment failure 10%
Teitelbaum et al. (26) 11 Children TED 4–6 weeks No improvement
patients), which was attributed by the authors to the poor dietary
compliance (6).
The performance of diet treatment requires supervision by an
experienced dietitian to ensure compliance with the diet and that
proper amount of calories, vitamins, and micronutrients are main-
tained (11). Nutritional status of the patient needs to be evaluated
longitudinally in order to identify early nutritional impairment
and apply appropriate measures to reverse it (11).
HOW TO ASSESS THE EFFICACY OF THE DIET?
Histological response does not correlate with clinical response.
Relying on symptom reversal for the assessment of the efficacy of
a therapeutic intervention may be misleading, allowing perpetua-
tion of esophageal inflammation. The recommendation, therefore,
is to assess the efficacy of the chosen treatment with a repeat
endoscopy following resolution of symptoms after commenc-
ing dietary elimination (11). In case AAF is chosen, the repeat
endoscopy may be performed at 4 weeks as the resolution of symp-
toms is achieved earlier. In case of TED or EED, the resolution of
symptoms is expected later and therefore the repeat endoscopy is
suggested at 8–12 weeks from the introduction. In case of histo-
logical remission, food reintroduction is considered starting from
the least allergenic foods (30). During food reintroduction, those
foods that prove to trigger EoE symptoms may need to be indef-
initely restricted (1). Some units advise the invasive approach
of performing periodic endoscopies to assure maintenance of
combined symptomatic and histological remission following food
reintroduction and suggest a re-endoscopy after reintroduction
of all of the foods of similar allergenicity from vegetables, fruits,
grains, and meat. More studies are required to show whether
the measurement of specific inflammatory mediators through
non-invasive techniques may allow an easier monitoring of the
tolerance to specific foods.
As stated above, dietary treatment is particularly effective in
treating EoE in atopic children. Patients without a history of atopy
are relatively refractory to dietary treatment and require initiation
of drug therapy (31). In some patients, there is evidence that sea-
sonal exacerbations caused by inhaled aeroallergens (including
pollens and molds) may occur, often characterized by food bolus
impaction (32). It is, therefore, important to enquire about sea-
sonal exacerbations and, if present, to try to identify triggering
aeroallergens. In case of an established pattern of seasonal exacer-
bations, preventive measures with dietary restrictions and/or the
use of topical corticosteroids may be suggested.
DRUG THERAPY
Among the medications that have been assessed in pediatric
patients with EoE with different success, are corticosteroids (oral
systemic and topical), cromolyn sodium, leukotriene receptor
antagonists, and biologics (mainly anti-IgE and anti-IL-5 mon-
oclonal antibodies). From those, only oral systemic and topical
corticosteroids proved to be highly effective in treating children
with EoE (Table 2). It should be noted, however, that there are
only few randomized controlled trials assessing the efficacy of dif-
ferent drug agents, therefore, further studies are needed to have a
universal approach to EoE treatment.
TOPICAL AND SYSTEMIC ORAL STEROIDS
Oral systemic and topical steroids are both highly effective in
inducing clinical and histological remission in adults and in chil-
dren with EoE with minor side effects such as oral candidiasis,
resolving following drug discontinuation. The clinical remission
following oral steroids is achieved as early as at 1 week from
the start of treatment and the resolution of histologic lesions
at 4 weeks (33). Unfortunately, the discontinuation of drug ther-
apy is often associated with relapse of the disease and the need
for a repeated course of treatment. Considering, therefore, the
risks associated with the chronic use of oral systemic steroids
in children, topical steroids were assessed in patients with EoE
and proved effective in achieving resolution of histologic lesions.
Studies showed that although oral prednisone achieved a greater
degree of histologic regression, there was no statistical difference
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Table 2 | Outcomes of studies on steroid therapy of eosinophilic esophagitis.
Reference No of patients Treatment Duration Outcome
Liacouras et al. (33) 20 Children Oral steroids 4 weeks Clinical and histological response in all
Teitelbaum et al. (26) 11 Children Topical FP open label 8 weeks Clinical and histological response in all
Remedios et al. (35) 19 Adults Topical FP open label 4 weeks Clinical and histological response in all
Konikoff et al. (36) 36 Children Topical FP randomised
controlled trial






Dohil et al. (38) 24 Children Topical OVB DBCT 12 weeks Clinical improvement
OVB: in 87%
Placebo: in none
Histological improvement OVB: in 87%
Placebo: in 0%
Straumann et al. (39) 36 Adolescents
and adults
Topical OVB DBCT 2 weeks Clinical improvement
OVB: in 72%
Placebo: in 22% histological
improvement following OVB but not
following placebo
with regards to symptom resolution, symptom relapse, or time
of relapse (34). The use of systemic corticosteroids, therefore, is
only considered when immediate relief of the patient’s symptoms
such as severe dysphagia, dehydration, weight loss, or esophageal
strictures, is needed. In all other case, the topical steroids are con-
sidered as first line drug treatment for EoE. The effective dose
for eliminating clinical symptoms and histologic abnormalities
is 1–2 mg/kg/day of prednisone with maximum dose reaching
40–60 mg.
The topical steroids, which have been used in treating EoE,
are swallowed fluticasone propionate and oral viscous budesonide
(OVB). Fluticasone propionate is sprayed into the mouth with
lips sealed around the device and the patient is advised to not
drink or eat for the next 30 min (35). This drug was effective in
both adults (35) and children (26) with EoE and was reported
to induce remission in 50 (36) to 91% of the patients (37). The
suggested dosage ranges from 88 to 440µg twice to four times
daily for children and 440–880µg twice daily for adolescents/
adults (1).
Oral viscous budesonide is also an option for treating EoE. It is
prepared by mixing liquid solution of budesonide 1 mg/2 ml (the
preparation used for inhalations) and 5 g of sucralose. The admin-
istration of this preparation achieves regression of symptoms and
of endoscopic and histologic abnormalities in 87% of children (38)
and in 72% of adolescents and adults with EoE (39). The recom-
mended dosage of OVB is 1 mg daily for children <10 years and
2 mg daily for older children and adults (1). Both topical prepa-
rations may induce remission of inflammation as documented in
various studies but the OVB may provide increased concentration
of the drug in the esophagus (40).
Drug titration should be initiated after confirming histologic
remission following symptoms resolution with a repeat endoscopy,
at 4–12 weeks following drug introduction (11).
It should be noted, however, that similarly to oral systemic
corticosteroids, the discontinuation of topical steroids is asso-
ciated with relapse of symptoms as early as at 4 months (38)
or according to others at a mean time of 8.8 months (37)
requiring maintenance therapy. In adults with EoE, a low-dose
(twice daily 0.25 mg) of OVB maintained quiescent EoE in
remission (41). In children, although the need for maintenance
treatment is often recognized, the optimal regimen still needs to be
determined.
OTHER DRUG THERAPIES
Other drug therapies such as sodium cromoglycate or mon-
telukast, a leukotriene receptor antagonist, are not recommended
for treating EoE unless more favorable data become avail-
able (1, 11). The same is true for immunomodulating drugs
and biologics (42). The efficacy of antibodies against IL-5 in
patients with EoE is controversial showing variable results and
relapse upon discontinuation, while anti-IgE monoclonal anti-
bodies were effective in improving food tolerance and revers-
ing symptoms but not in improving endoscopic and histological
abnormalities (43).
FOLLOW-UP OF ASYMPTOMATIC PATIENTS
The follow-up of asymptomatic patients is not universal and
differs widely among centers with some performing periodic
endoscopic re-evaluations while, others not. Considering that
long-term complications of the asymptomatic disease are poorly
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defined, the follow-up of asymptomatic patients should be indi-
vidualized considering disease phenotype and severity (11).
As mentioned above, there may be a discrepancy between symp-
toms and histological features. Medical advice may be therefore
guided to promote inflammation-free esophageal mucosa with
follow-up endoscopies, but this ambitious goal has to be adjusted
to individual patients.
ESOPHAGEAL DILATATION
Esophageal dilatation (ED) has been used mainly in adults with
EoE (44). ED can be helpful in acutely symptomatic patients who
present with severe dysphagia due to marked esophageal narrow-
ing after failure of medical treatment to improve symptoms (45).
It should be stressed, however, that before deciding on ED, it is
mandatory to try medical and/or dietary therapy (11).
CONCLUSION
Eosinophilic esophagitis is a chronic, relapsing inflammatory dis-
ease of the esophagus, which requires often repeated or prolonged
therapy. The definition of the disease phenotypes, and the develop-
ment of biomarkers, to evaluate the response to treatment and the
early relapse, will allow guide more precisely short- and long-term
management of the disease.
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APPENDIX
KEY POINTS
A trial with antisecretory medication is necessary to exclude GERD and PPI-responsive esophageal eosinophilia and to fulfill the
diagnostic criteria of EoE.
Elimination diet and/or off-label use of topical corticosteroids are effective measures for treating EoE.
Elimination diet is the first line treatment in atopic children.
Systemic corticosteroids are reserved for patients with severe disease requiring immediate relief, or when other treatments have failed.
Cromolyn sodium (sodium cromoglycate) and leukotriene receptor antagonists are not currently recommended for treating EoE due
to lack of solid evidence of benefit.
Immunosuppressive drugs and biologics have shown some value but effect has been limited and therefore not yet recommended as
standard therapy.
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